From: Metabolic engineering of Lactobacilli spp. for disease treatment
Strains | Strategy | Expression mode | Mechanisms | Diseases | Treating effect | Experimental model | Reference |
---|---|---|---|---|---|---|---|
Displaying vaccines for treating viruses infection | |||||||
L. salivarius TCMM17 | Surface displaying the EpiC of IBV | Genome integration | Stimulating immunity responses | Against IBV | Â | Â | [53] |
L. acidophilus NCFM | Surface displaying the VP8* domain of the rotavirus EDIM VP4 capsid protein along with the adjuvants FimH and FliC | Genome integration | Inducing the anti-rotavirus serum IgG and antigen-specific antibody-secreting cell responses | Against rotavirus diarrhea-associated illness | Reducing the fecal shedding of rotavirus antigen (4-fold) | BALB/cJ mice challenged with murine rotavirus strain ECWT | [54] |
Displaying functional element for the intestinal exclusion of virus | |||||||
L. acidophilus ATCC 4356 | Surface displaying the HIV-1 receptor CD4 of human beings | Genome integration | Adsorbing HIV-1 particles to block intrarectal HIV-1 infection | Against human HIV-1 infection | Decreasing the infection rate (57% reduction) of the HIV-1-challenged mice | Bone marrow, liver, and thymus (BLT) humanized mice challenged with HIV-1 JR-CSF | [55] |
Displaying pharmaceutical compound | |||||||
L. casei ATCC 393 | Surface displaying the lactoferricin (Lfcin) polypeptide | Genome integration | Modulating host immune responses; Inducing autolysis death of bacteria cell by increasing its membrane permeability; Blocking the iron intake of microorganisms to act antimicrobial activity | Against Escherichia coli, Staphylococcus aureus, and PEDV | This engineered strain showed good antibacterial activity against E. coli (40.05% inhibition) and S. aureus (42.22% inhibition) and antiviral activity against PEDV (2-fold suppression of viral replication) | VERO cells infected with PEDV | [56] |